NCT02218099View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2013

Primary Completion Date

September 9, 2014

Study Completion Date

September 9, 2014

Conditions

Healthy SubjectsPharmacokinetics of ASP8232Pharmacodynamics of ASP8232Chronic Kidney Disease (CKD)Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

ASP8232

Oral

DRUG

Placebo

Oral

Trial Locations (3)

1612

Site: 35901, Sofia

10731

Site: 40001, Bucharest

Unknown

Site: 37301, Chisinau

All Listed Sponsors

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT02218099 - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter